Cytosorbents (NASDAQ:CTSO) was awarded a Defense Health Agency Small Business Technology Transfer (STTR) Phase III contract valued at up to $2.9 million over a two-year period, enabling CTSO to move ...
Q2 revenue came in at $33k (compared to our $19k estimate), representing sales during the initial test market roll-out. Operating expenses were $1.03 million, slightly below our $1.15 million estimate ...
StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO – Free Report) in a research report released on Wednesday. The brokerage issued a hold rating on the medical research company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results